Brian Rini, MD of Cleveland Clinic gives an overview of his poster presentation which focuses on the use of sunitinib in advanced/metastatic renal cell carcinoma at the 2017 ASCO Annual Meeting in Chicago, IL.
TPS4597: Phase 3 KEYNOTE-426 trial: pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naïve advanced/metastatic renal cell carcinoma (mRCC)
Advertisement